Immunor AS and its precursors have benefited from circa $100 million investment in diagnostic and vaccine-related technology research and development.
The fruit of that investment was the precursor and now the proven CPSPVP platform. In several Norwegian and international human clinical studies, Immunor has developed and tested HIV vaccine candidates Vacc-4x, Vacc-C5 (to be combined as Vacc-45). In combination with its HIV entry inhibitor drug, CRX, Immunor now has designed the world’s first vaccine-drug functional cure for HIV. The statistically significant clinical results for Vacc-4x are still the best clinical results for any HIV vaccine.